相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Comparison of acute gastrointestinal toxicities between 3-dimensional conformal radiotherapy and intensity-modulated radiotherapy including prophylactic regions in chemoradiotherapy with S-1 for pancreatic cancer-importance of dose volume histogram parameters in the stomach as the predictive factors
Rei Umezawa et al.
JOURNAL OF RADIATION RESEARCH (2022)
Factors Predicting Response, Perioperative Outcomes, and Survival Following Total Neoadjuvant Therapy for Borderline/Locally Advanced Pancreatic Cancer
Mark J. Truty et al.
ANNALS OF SURGERY (2021)
Staging laparoscopy is mandatory for the treatment of pancreatic cancer to avoid missing radiologically negative metastases
Tatsuyuki Takadate et al.
SURGERY TODAY (2021)
Comparison between FOLFIRINOX and gemcitabine plus nab-paclitaxel including sequential treatment for metastatic pancreatic cancer: a propensity score matching approach
Jung Won Chun et al.
BMC CANCER (2021)
Gemcitabine Plus Nab-Paclitaxel Versus FOLFIRINOX in Locally Advanced, Unresectable Pancreatic Cancer A Multicenter Observational Study (NAPOLEON Study)
Shiho Arima et al.
PANCREAS (2021)
The Survival Benefit of Chemoradiotherapy following Induction Chemotherapy with Gemcitabine Plus Nab-Paclitaxel for Unresectable Locally Advanced Pancreatic Cancer
Ryoji Takada et al.
CANCERS (2021)
Randomized phase II study of chemoradiotherapy with versus without induction chemotherapy for locally advanced pancreatic cancer: Japan Clinical Oncology Group trial, JCOG1106
Tatsuya Ioka et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2021)
Phase 2 Trial of Neoadjuvant FOLFIRINOX and Intensity Modulated Radiation Therapy Concurrent With Fixed-Dose Rate-Gemcitabine in Patients With Borderline Resectable Pancreatic Cancer
Nguyen H. Tran et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2020)
Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial
Eva Versteijne et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study
Philip A. Philip et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2020)
Outcomes of patients with initially locally advanced pancreatic adenocarcinoma who did not benefit from resection: a prospective cohort study
Jonathan Garnier et al.
BMC CANCER (2020)
Intensified systemic therapy and stereotactic ablative radiotherapy dose for patients with unresectable pancreatic adenocarcinoma
Diego A. S. Toesca et al.
RADIOTHERAPY AND ONCOLOGY (2020)
Prognostic impact of intraoperative peritoneal cytology after neoadjuvant therapy for potentially resectable pancreatic cancer
Shuichi Aoki et al.
PANCREATOLOGY (2020)
Gemcitabine plus nab-paclitaxel for locally advanced or borderline resectable pancreatic cancer
Akiko Tsujimoto et al.
SCIENTIFIC REPORTS (2019)
How Does Chemoradiotherapy Following Induction FOLFIRINOX Improve the Results in Resected Borderline or Locally Advanced Pancreatic Adenocarcinoma? An AGEO-FRENCH Multicentric Cohort
Daniel Pietrasz et al.
ANNALS OF SURGICAL ONCOLOGY (2019)
FOLFIRINOX for locally advanced pancreatic cancer: Results and prognostic factors of subset analysis from a nation-wide multicenter observational study in Japan
Ippei Matsumoto et al.
PANCREATOLOGY (2019)
International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017
Shuji Isaji et al.
PANCREATOLOGY (2018)
Tumor Reduction in Primary and Metastatic Pancreatic Cancer Lesions With nab-Paclitaxel and Gemcitabine An Exploratory Analysis From a Phase 3 Study
Volker Kunzmann et al.
PANCREAS (2017)
Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancer
Stacey M. Stein et al.
BRITISH JOURNAL OF CANCER (2016)
Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib The LAP07 Randomized Clinical Trial
Pascal Hammel et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
Prognostic Value of Occult Tumor Cells Obtained by Peritoneal Lavage in Patients With Resectable Pancreatic Cancer and No Ascites: A Systematic Review
Willemijn Steen et al.
JOURNAL OF SURGICAL ONCOLOGY (2016)
Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01)
Katsuhiko Uesaka et al.
LANCET (2016)
FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis
Mustafa Suker et al.
LANCET ONCOLOGY (2016)
FOLFIRINOX Induction Therapy for Stage 3 Pancreatic Adenocarcinoma
Eran Sadot et al.
ANNALS OF SURGICAL ONCOLOGY (2015)
Induction Gemcitabine Plus Concurrent Gemcitabine and Radiotherapy for Locally Advanced Unresectable or Resected Pancreatic Cancer
M. Youl et al.
CLINICAL ONCOLOGY (2014)
A Multicenter Phase II Trial of S-1 With Concurrent Radiation Therapy for Locally Advanced Pancreatic Cancer
Masafumi Ikeda et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2013)
Adjuvant Chemotherapy With Gemcitabine and Long-term Outcomes Among Patients With Resected Pancreatic Cancer The CONKO-001 Randomized Trial
Helmut Oettle et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2013)
Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial
Somnath Mukherjee et al.
LANCET ONCOLOGY (2013)
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Daniel D. Von Hoff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Gemcitabine Alone Versus Gemcitabine Plus Radiotherapy in Patients With Locally Advanced Pancreatic Cancer: An Eastern Cooperative Oncology Group Trial
Patrick J. Loehrer et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Thierry Conroy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
A randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer
H. Ueno et al.
BRITISH JOURNAL OF CANCER (2009)
DPC4 Gene Status of the Primary Carcinoma Correlates With Patterns of Failure in Patients With Pancreatic Cancer
Christine A. Iacobuzio-Donahue et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer.: Definitive results of the 2000-01 FFCD/SFRO study
B. Chauffert et al.
ANNALS OF ONCOLOGY (2008)
CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial
Viviane Hess et al.
LANCET ONCOLOGY (2008)
Tumor size significantly correlates with postoperative liver metastases and COX-2 expression in patients with resectable pancreatic cancer
Gaku Matsumoto et al.
PANCREATOLOGY (2007)
Locally advanced pancreatic cancer
CG Willett et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
分享论文
